Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy
NCT ID: NCT05430828
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
5000 participants
OBSERVATIONAL
2020-03-07
2030-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)
NCT03397121
Cross-over Study of Coronary Risk Factors With a Polypill
NCT05030818
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH
NCT03933293
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study
NCT01516879
Efficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
NCT00141141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Subjects with hyperlipidaemia under PCSK9 inhibitors treatment (Repatha/Praulent).
Repatha (evolocumab); Praluent (alirocumab)
Dosage form: Injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repatha (evolocumab); Praluent (alirocumab)
Dosage form: Injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients who refuse to participate and to sign informed consent.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Federico II University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pasquale Perrone Filardi
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedali dell'Ovest Vicentino
Arzignano, , Italy
University of Bari Aldo Moro
Bari, , Italy
University of Campania Luigi Vanvitelli
Caserta, , Italy
University Magna Graecia of Catanzaro
Catanzaro, , Italy
Presidio Ospedaliero Maria SS Addolorata
Eboli, , Italy
Policlinico Riuniti Foggia
Foggia, , Italy
Università degli Studi di Genova
Genova, , Italy
Ospedale di Lecce
Lecce, , Italy
Università degli Studi di Messina
Messina, , Italy
Policlinico di Milano Ospedale Maggiore - Fondazione IRCCS Ca' Granda
Milan, , Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, , Italy
AORN dei Colli - Ospedale monaldi
Napoli, , Italy
Federico II University of Naples, Department of Advanced Biomedical Sciences
Napoli, , Italy
Federico II University of Naples, Department of Translational Medical Sciences
Napoli, , Italy
University of Naples Federico II, Department of Clinical Medicine and Surgery
Napoli, , Italy
Azienda Ospedaliero-Universitaria "Maggiore della Carità"
Novara, , Italy
Azienda Ospedaliero-Univeristaria di Parma
Parma, , Italy
Presidio Ospedaliero Pescara
Pescara, , Italy
Ospedale di Rivoli
Rivoli, , Italy
Policlinico Tor Vergata
Roma, , Italy
Azienda Ospedaliera San Camillo-Forlanini
Roma, , Italy
Policlinico Casilino
Roma, , Italy
Sapienza University of Rome
Roma, , Italy
Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona
Salerno, , Italy
Ospedale SS Annunziata A.O.U.
Sassari, , Italy
University of Siena
Siena, , Italy
Azienda Ospedaliera Ordine Mauriziano Torino
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Claudio Bilato, MD
Role: primary
Marco Matteo Ciccone, MD
Role: primary
Paolo Calabrò, MD
Role: primary
Ciro Indolfi, MD
Role: primary
Angelo Catalano, MD
Role: primary
Natale Brunetti, MD
Role: primary
Italo Porto, MD
Role: primary
Giuseppe Colonna, MD
Role: primary
Giuseppe Andò, MD
Role: primary
Stefano Carugo, MD
Role: primary
Piera Merlini, MD
Role: primary
Mario Crisci, MD
Role: primary
Pasquale Perrone Filardi, MD
Role: primary
Francesco Giallauria, MD
Role: primary
Gabriella Iannuzzo, MD
Role: primary
Giuseppe Patti, MD
Role: primary
Giampaolo Niccoli, MD
Role: primary
Leonardo Paloscia, MD
Role: primary
Fernando Varbella, MD
Role: primary
Saverio Muscoli, MD
Role: primary
Leonardo De Luca, MD
Role: primary
Leonardo Calò, MD
Role: primary
Gennaro Galasso, MD
Role: primary
Gavino Casu, MD
Role: primary
Matteo Cameli, MD
Role: primary
Giuseppe Musumeci, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
264/20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.